A Study to Investigate the Feasibility of Administration of a Speech Battery and the Use of Speech-based Biomarkers for the Clinical Assessment of Common Neurodegenerative and Psychiatric Disorders in a Remote Setting.

Study Purpose:

The primary objective of the study is to evaluate the feasibility of eliciting continuous narrative speech in different neurodegenerative and psychiatric indications, using remote, self-administered speech tasks, as measured by the average length of speech elicitation for each speech task during the first week of self-assessment. Secondary objectives include (1) evaluating the reliability of speech tasks in the remote self-administered setting, as measured by the intra- and inter-subject variance; (2) accessing the adherence of speech tasks in this setting, as measured by the subject average fraction of days during the first week, where at least one task response is submitted; (3) evaluating the feasibility of using speech tasks in the setting of a telemedicine videoconference, as measured by the average length of speech elicited in each group; (4) evaluate whether a set of acoustic and linguistic patterns can detect each indication, compare to either a control group or all other indications, as measured by the area under the receiver operating characteristic curve (AUC), sensitivity, specificity and Cohen's kappa of the relevant binary classifier; (5) evaluating how the performance of such algorithms can be impacted by speaker and environment covariates, as measured by the Kendall rank correlation coefficient of the AUC of each classifier and each of age group, gender and speech-to-reverberation modulation energy ratio.

Study Status:

Recruiting

Disease:

Alzheimer Disease , Mild Cognitive Impairment , Dementia With Lewy Bodies , Dementia, Vascular , Frontotemporal Dementia , Primary Progressive Aphasia , Parkinson Disease , Motor Neuron Disease , Major Depressive Disorder , Bipolar Disorder , Amyotrophic Lateral Sclerosis

Study Type:

Observational [Patient Registry]

Type of Intervention:

N/A

Intervention Name:

N/A

Placebo:

N/A

Phase:

N/A

Study Chair(s)/Principal Investigator(s):

Allan Young, Professor, King's College London

Clinicaltrials.gov ID:

NCT04939818

Neals Affiliated?

No

Coordinating Center Contact Information

Study Sponsor:

Novoic Limited

Estimated Enrollment:

250

Estimated Study Start Date:

06 / 14 / 2021

Estimated Study Completion Date:

06 / 15 / 2022

Posting Last Modified Date:

02 / 28 / 2022

Date Study Added to neals.org:

06 / 25 / 2021